Selected Grants
A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients with Early Symptomatic AD
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2035DNA09-A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Immunovant · 2025 - 2034A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients with Early Symptomatic Alzheimer's Disease
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2029A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis, followed by an open-label extension phase
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029The ME&MG digital solution for autonomous assessment of Myasthenia Gravis: a validation study
ResearchPrincipal Investigator · Awarded by Ad Scientiam · 2024 - 2026A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG.
Clinical TrialPrincipal Investigator · Awarded by Immunovant · 2023 - 2026Phase 1 Clinical Trials for Development of Neurotherapeutics Performance
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2026"A Multicenter, Open Label, Phase 1b Study to Evaluate Safety, Pharmacodynamics and Efficacy of RVP 001 in Adult Patients with Known CNS Lesions and Who Have Undergone GBCA Enhanced MRI"
Clinical TrialPrincipal Investigator · Awarded by Reveal Pharmaceuticals, Inc. · 2024 - 202618-0006 Mod 6 (EA)
Clinical TrialSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2025A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS),
Clinical TrialPrincipal Investigator · Awarded by Bayer HealthCare Pharmaceuticals, Inc · 2023 - 2025A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS),
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2024 - 2025PTN2: Trial Designs for Dosing/Safety and Efficacy in Pediatric Therapeutics_TO5; PTN-TBS02, Adult Terbutaline - DUK99
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2022 - 2025An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of OV329 in Healthy Male and Female Participants
Clinical TrialPrincipal Investigator · Awarded by Ovid Therapeutics · 2022 - 2024Healthy Volunteer Study of CSF fluid and Oral Bioavailability of RR-HNK
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2024Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2018 - 2024Evaluation of the iMOST X Morphology Flagging
ResearchPrincipal Investigator · Awarded by Essenlix Corporation · 2022 - 2023Real World Outcomes of Surgical and Medical Management in Myasthenia Gravis
ResearchPrincipal Investigator · Awarded by American Academy of Neurology · 2019 - 2022Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption
Clinical TrialPrincipal Investigator · Awarded by Vivante Health · 2021 - 2022RTOP 18-0006 Option 1 / Protocol Implementation
Clinical TrialSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2022Phase 1 single-ascending dose study of the safety and pharmacokinetics of 24 hour intravenous 5-HTP (EVX-301)
Clinical TrialPrincipal Investigator · Awarded by EVECXIA Therapeutics · 2020 - 2020AANEM Autoimmune Neuromuscular Disorders Fellowship
FellowshipPI-Fellow · Awarded by AANEM Foundation for Research & Education · 2017 - 2018External Relationships
- Ocaro Pharmaceuticals
- Ovid Therapeutics
- Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.